167.8K XNAS Volume
XNAS 18 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Frederick B. Craves | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 111.06 per share. | 12 Mar 2025 | 6,000 | 357,804 (2%) | 0% | 111.1 | 666,360 | Common Stock |
| Frederick B. Craves | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 65.06 per share. | 12 Mar 2025 | 1,728 | 351,804 (2%) | 0% | 65.1 | 112,424 | Common Stock |
| Frederick B. Craves | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2025 | 7,742 | 0 | - | - | Stock Option (Right to Buy) | |
| Frederick B. Craves | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2025 | 6,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Frederick B. Craves | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2025 | 1,728 | 7,742 | - | - | Stock Option (Right to Buy) | |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 330.23 per share. | 12 Mar 2025 | 75 | 350,076 (2%) | 0% | 330.2 | 24,767 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 329.86 per share. | 12 Mar 2025 | 967 | 350,151 (2%) | 0% | 329.9 | 318,975 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 328.68 per share. | 12 Mar 2025 | 400 | 351,118 (2%) | 0% | 328.7 | 131,472 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 327.63 per share. | 12 Mar 2025 | 1,000 | 351,518 (2%) | 0% | 327.6 | 327,627 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 325.63 per share. | 12 Mar 2025 | 800 | 352,518 (2%) | 0% | 325.6 | 260,501 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 324.69 per share. | 12 Mar 2025 | 900 | 353,318 (2%) | 0% | 324.7 | 292,218 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 323.47 per share. | 12 Mar 2025 | 1,649 | 354,218 (2%) | 0% | 323.5 | 533,394 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 322.45 per share. | 12 Mar 2025 | 1,951 | 355,867 (2%) | 0% | 322.5 | 629,100 | Common Stock |
| Frederick B. Craves | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 65.06 per share. | 12 Mar 2025 | 7,742 | 357,818 (2%) | 0% | 65.1 | 503,695 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 334.97 per share. | 12 Mar 2025 | 200 | 350,076 (2%) | 0% | 335.0 | 66,994 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 333.66 per share. | 12 Mar 2025 | 800 | 350,276 (2%) | 0% | 333.7 | 266,926 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 332.38 per share. | 12 Mar 2025 | 2,382 | 351,076 (2%) | 0% | 332.4 | 791,726 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 331.36 per share. | 12 Mar 2025 | 2,759 | 353,458 (2%) | 0% | 331.4 | 914,221 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 330.54 per share. | 12 Mar 2025 | 1,587 | 356,217 (2%) | 0% | 330.5 | 524,560 | Common Stock |
| Mardi C. Dier | SVP and CFO | Sale of securities on an exchange or to another person at price $ 323.04 per share. | 10 Mar 2025 | 258 | 10,440 (0%) | 0% | 323.0 | 83,344 | Common Stock |
| Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 1,579 | 1,579 | - | - | Stock Option (Right to Buy) | |
| Jacqualyn A. Fouse | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 894 | 894 (0%) | 0% | 0 | Common Stock | |
| Shannon T. Kelley | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 3,187 | 10,477 (0%) | 0% | 0 | Common Stock | |
| Shannon T. Kelley | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 5,368 | 5,368 | - | - | Stock Option (Right to Buy) | |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 1,157 | 1,157 | - | - | Stock Option (Right to Buy) | |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 4,382 | 461,044 (2%) | 0% | 0 | Common Stock | |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 7,381 | 7,381 | - | - | Stock Option (Right to Buy) | |
| William John Sibold | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 22,009 | 22,009 | - | - | Stock Option (Right to Buy) | |
| William John Sibold | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 13,066 | 117,369 (0%) | 0% | 0 | Common Stock | |
| Mardi C. Dier | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 6,374 | 6,374 | - | - | Stock Option (Right to Buy) | |
| Mardi C. Dier | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 3,784 | 10,698 (0%) | 0% | 0 | Common Stock | |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 344.76 per share. | 05 Mar 2025 | 1,412 | 3,728 (0%) | 0% | 344.8 | 486,797 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 343.85 per share. | 05 Mar 2025 | 4,701 | 5,140 (0%) | 0% | 343.8 | 1,616,429 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 342.90 per share. | 05 Mar 2025 | 1,077 | 9,841 (0%) | 0% | 342.9 | 369,300 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 341.84 per share. | 05 Mar 2025 | 1,043 | 10,918 (0%) | 0% | 341.8 | 356,537 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 340.75 per share. | 05 Mar 2025 | 1,657 | 11,961 (0%) | 0% | 340.8 | 564,627 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 338.09 per share. | 05 Mar 2025 | 1,146 | 14,018 (0%) | 0% | 338.1 | 387,452 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 336.78 per share. | 05 Mar 2025 | 1,777 | 15,164 (0%) | 0% | 336.8 | 598,457 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 335.15 per share. | 05 Mar 2025 | 900 | 16,941 (0%) | 0% | 335.1 | 301,631 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.09 per share. | 05 Mar 2025 | 7,288 | 17,841 (0%) | 0% | 87.1 | 634,712 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.92 per share. | 05 Mar 2025 | 6,825 | 10,553 (0%) | 0% | 87.9 | 600,054 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 339.68 per share. | 05 Mar 2025 | 400 | 13,618 (0%) | 0% | 339.7 | 135,874 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 7,288 | 3,062 | - | - | Stock Option (Right to Buy) | |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 6,825 | 4,375 | - | - | Stock Option (Right to Buy) | |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 2,061 | 5,789 (0%) | 0% | 0 | Common Stock | |
| Carole Huntsman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 5,703 | 5,703 | - | - | Stock Option (Right to Buy) | |
| Carole Huntsman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 3,386 | 11,990 (0%) | 0% | 0 | Common Stock | |
| Shannon T. Kelley | General Counsel | Sale of securities on an exchange or to another person at price $ 335.00 per share. | 03 Mar 2025 | 415 | 7,290 (0%) | 0% | 335 | 139,025 | Common Stock |
| Mardi C. Dier | SVP and CFO | Sale of securities on an exchange or to another person at price $ 323.54 per share. | 03 Mar 2025 | 774 | 6,914 (0%) | 0% | 323.5 | 250,417 | Common Stock |
| Mardi C. Dier | SVP and CFO | Sale of securities on an exchange or to another person at price $ 325.89 per share. | 03 Mar 2025 | 1,187 | 7,688 (0%) | 0% | 325.9 | 386,831 | Common Stock |
| Carole Huntsman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 314.74 per share. | 03 Mar 2025 | 200 | 10,167 (0%) | 0% | 314.7 | 62,948 | Common Stock |
| Carole Huntsman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 313.08 per share. | 03 Mar 2025 | 71 | 10,367 (0%) | 0% | 313.1 | 22,229 | Common Stock |
| Carole Huntsman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 335.00 per share. | 03 Mar 2025 | 563 | 8,604 (0%) | 0% | 335 | 188,605 | Common Stock |
| Carole Huntsman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 329.64 per share. | 03 Mar 2025 | 100 | 9,167 (0%) | 0% | 329.6 | 32,964 | Common Stock |
| Carole Huntsman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 327.49 per share. | 03 Mar 2025 | 100 | 9,267 (0%) | 0% | 327.5 | 32,749 | Common Stock |
| Carole Huntsman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 326.34 per share. | 03 Mar 2025 | 100 | 9,367 (0%) | 0% | 326.3 | 32,634 | Common Stock |
| Carole Huntsman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 324.59 per share. | 03 Mar 2025 | 200 | 9,467 (0%) | 0% | 324.6 | 64,918 | Common Stock |
| Carole Huntsman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 323.65 per share. | 03 Mar 2025 | 200 | 9,667 (0%) | 0% | 323.7 | 64,730 | Common Stock |
| Carole Huntsman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 320.21 per share. | 03 Mar 2025 | 300 | 9,867 (0%) | 0% | 320.2 | 96,063 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 340.99 per share. | 28 Feb 2025 | 1,052 | 3,903 (0%) | 0% | 341.0 | 358,717 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 341.55 per share. | 28 Feb 2025 | 175 | 3,728 (0%) | 0% | 341.5 | 59,771 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 355.08 per share. | 27 Feb 2025 | 8,545 | 12,529 (0%) | 0% | 355.1 | 3,034,150 | Common Stock |
| Kenneth M. Bate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 111.06 per share. | 27 Feb 2025 | 6,000 | 7,912 (0%) | 0% | 111.1 | 666,360 | Common Stock |
| Kenneth M. Bate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 65.06 per share. | 27 Feb 2025 | 9,470 | 17,382 (0%) | 0% | 65.1 | 616,118 | Common Stock |
| Kenneth M. Bate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 27 Feb 2025 | 4,530 | 21,912 (0%) | 0% | 9.5 | 42,809 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 351.01 per share. | 27 Feb 2025 | 100 | 21,812 (0%) | 0% | 351.0 | 35,101 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 351.99 per share. | 27 Feb 2025 | 500 | 21,312 (0%) | 0% | 352.0 | 175,995 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 353.84 per share. | 27 Feb 2025 | 238 | 21,074 (0%) | 0% | 353.8 | 84,213 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 357.27 per share. | 27 Feb 2025 | 2,038 | 7,700 (0%) | 0% | 357.3 | 728,109 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 356.51 per share. | 27 Feb 2025 | 2,791 | 9,738 (0%) | 0% | 356.5 | 995,016 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 359.21 per share. | 27 Feb 2025 | 2,024 | 2,128 (0%) | 0% | 359.2 | 727,042 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 358.33 per share. | 27 Feb 2025 | 3,548 | 4,152 (0%) | 0% | 358.3 | 1,271,359 | Common Stock |
| Kenneth M. Bate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 4,530 | 5,470 | - | - | Stock Option (Right to Buy) | |
| Kenneth M. Bate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 9,470 | 0 | - | - | Stock Option (Right to Buy) | |
| Kenneth M. Bate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 6,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 360.06 per share. | 27 Feb 2025 | 216 | 1,912 (0%) | 0% | 360.1 | 77,774 | Common Stock |
| William John Sibold | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 50,000 | 104,303 (0%) | 0% | - | Common Stock | |
| William John Sibold | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 50,000 | 0 | - | - | Performance Restricted Stock Units | |
| James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 9,470 | 0 | - | - | Stock Option (Right to Buy) | |
| James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 65.06 per share. | 27 Feb 2025 | 9,470 | 11,382 (0%) | 0% | 65.1 | 616,118 | Common Stock |
| James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 111.06 per share. | 27 Feb 2025 | 6,000 | 17,382 (0%) | 0% | 111.1 | 666,360 | Common Stock |
| James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 346.90 per share. | 27 Feb 2025 | 398 | 16,984 (0%) | 0% | 346.9 | 138,067 | Common Stock |
| James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 347.39 per share. | 27 Feb 2025 | 14,302 | 2,682 (0%) | 0% | 347.4 | 4,968,372 | Common Stock |
| James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 348.94 per share. | 27 Feb 2025 | 770 | 1,912 (0%) | 0% | 348.9 | 268,686 | Common Stock |
| James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 6,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 335.24 per share. | 24 Jan 2025 | 648 | 456,662 (2%) | 0% | 335.2 | 217,236 | Common Stock |
| William John Sibold | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 335.24 per share. | 24 Jan 2025 | 1,584 | 54,303 (0%) | 0% | 335.2 | 531,020 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 335.24 per share. | 24 Jan 2025 | 103 | 4,955 (0%) | 0% | 335.2 | 34,530 | Common Stock |
| Carole Huntsman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 335.24 per share. | 24 Jan 2025 | 347 | 10,438 (0%) | 0% | 335.2 | 116,328 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 273.41 per share. | 17 Jan 2025 | 1,689 | 457,310 (2%) | 0% | 273.4 | 461,789 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 273.41 per share. | 17 Jan 2025 | 442 | 5,058 (0%) | 0% | 273.4 | 120,847 | Common Stock |
| Shannon T. Kelley | General Counsel | Sale of securities on an exchange or to another person at price $ 273.41 per share. | 17 Jan 2025 | 277 | 7,705 (0%) | 0% | 273.4 | 75,735 | Common Stock |
| Craves Frederick B. | Director | Sale of securities on an exchange or to another person at price $ 315.21 per share. | 03 Dec 2024 | 3,080 | 11,520 (0%) | 0% | 315.2 | 970,852 | Common Stock |
| Craves B. Frederick | Director | Sale of securities on an exchange or to another person at price $ 315.90 per share. | 03 Dec 2024 | 520 | 11,000 (0%) | 0% | 315.9 | 164,270 | Common Stock |
| Craves B. Frederick | Director | Sale of securities on an exchange or to another person at price $ 350.72 per share. | 25 Nov 2024 | 1,200 | 14,600 (0%) | 0% | 350.7 | 420,858 | Common Stock |
| B. Craves Frederick | Director | Sale of securities on an exchange or to another person at price $ 350.08 per share. | 25 Nov 2024 | 2,200 | 15,800 (0%) | 0% | 350.1 | 770,171 | Common Stock |
| Carole Huntsman | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 316.92 per share. | 21 Nov 2024 | 688 | 10,785 (0%) | 0% | 316.9 | 218,041 | Common Stock |
| Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.36 per share. | 07 Nov 2024 | 5,000 | 16,012 (0%) | 0% | 7.4 | 36,800 | Common Stock |
| Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 5,000 | 5,000 | - | - | Stock Option (Right to Buy) | |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 350.00 per share. | 07 Nov 2024 | 5,000 | 11,012 (0%) | 0% | 350 | 1,750,000 | Common Stock |
| Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.36 per share. | 01 Nov 2024 | 5,000 | 16,012 (0%) | 0% | 7.4 | 36,800 | Common Stock |
| Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 5,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 304.29 per share. | 01 Nov 2024 | 300 | 11,012 (0%) | 0% | 304.3 | 91,287 | Common Stock |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 302.25 per share. | 01 Nov 2024 | 800 | 11,312 (0%) | 0% | 302.2 | 241,799 | Common Stock |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 301.22 per share. | 01 Nov 2024 | 1,100 | 12,112 (0%) | 0% | 301.2 | 331,339 | Common Stock |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 300.10 per share. | 01 Nov 2024 | 2,800 | 13,212 (0%) | 0% | 300.1 | 840,278 | Common Stock |
| Frederick B. Craves | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Sep 2024 | 15,000 | 360,076 (2%) | 0% | 0 | Common Stock | |
| William John Sibold | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 243.83 per share. | 09 Sep 2024 | 6,363 | 55,887 (0%) | 0% | 243.8 | 1,551,490 | Common Stock |
| Shannon T. Kelley | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 5,215 | 7,982 (0%) | 0% | 0 | Common Stock | |
| Shannon T. Kelley | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 7,820 | 7,820 | - | - | Stock Option (Right to Buy) | |
| Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 714 | 186,449 (1%) | 0% | 0 | Common Stock | |
| Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 1,105 | 1,105 | - | - | Stock Option (Right to Buy) | |
| Frederick B. Craves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 714 | 375,076 (2%) | 0% | 0 | Common Stock | |
| Frederick B. Craves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 1,105 | 1,105 | - | - | Stock Option (Right to Buy) | |
| Kenneth M. Bate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 714 | 1,912 (0%) | 0% | 0 | Common Stock | |
| Kenneth M. Bate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 1,105 | 1,105 | - | - | Stock Option (Right to Buy) | |
| Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 714 | 11,012 (0%) | 0% | 0 | Common Stock | |
| Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 1,105 | 1,105 | - | - | Stock Option (Right to Buy) | |
| James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 1,105 | 1,105 | - | - | Stock Option (Right to Buy) | |
| James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2024 | 714 | 1,912 (0%) | 0% | 0 | Common Stock | |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 1,900 | 10,350 | - | - | Stock Option (Right to Buy) | |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.09 per share. | 14 Jun 2024 | 1,900 | 7,400 (0%) | 0% | 87.1 | 165,471 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 280.00 per share. | 14 Jun 2024 | 1,900 | 5,500 (0%) | 0% | 280 | 532,000 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 2,000 | 15,200 | - | - | Stock Option (Right to Buy) | |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 285.00 per share. | 12 Jun 2024 | 2,000 | 5,500 (0%) | 0% | 285 | 570,000 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.92 per share. | 12 Jun 2024 | 2,000 | 7,500 (0%) | 0% | 87.9 | 175,840 | Common Stock |
| Frederick B. Craves | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Jun 2024 | 39,000 | 374,362 (2%) | 0% | 0 | Common Stock | |
| Frederick B. Craves | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Jun 2024 | 45,852 | 11,210 (0%) | 0% | 0 | Common Stock | |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 231.34 per share. | 21 May 2024 | 1,036 | 5,500 (0%) | 0% | 231.3 | 239,668 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 217.86 per share. | 14 May 2024 | 1,100 | 414,462 (2%) | 0% | 217.9 | 239,641 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 210.99 per share. | 14 May 2024 | 8,827 | 427,024 (2%) | 0% | 211.0 | 1,862,432 | Common Stock |
| Frederick B. Craves | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 105.08 per share. | 14 May 2024 | 12,489 | 435,851 (2%) | 0% | 105.1 | 1,312,344 | Common Stock |
| Frederick B. Craves | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.45 per share. | 14 May 2024 | 10,000 | 423,362 (2%) | 0% | 100.5 | 1,004,500 | Common Stock |
| Frederick B. Craves | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 12,489 | 0 | - | - | Stock Option (right to buy) | |
| Frederick B. Craves | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 219.90 per share. | 14 May 2024 | 100 | 413,362 (2%) | 0% | 219.9 | 21,990 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 219.00 per share. | 14 May 2024 | 1,000 | 413,462 (2%) | 0% | 219.0 | 218,995 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 216.98 per share. | 14 May 2024 | 721 | 415,562 (2%) | 0% | 217.0 | 156,445 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 216.08 per share. | 14 May 2024 | 375 | 416,283 (2%) | 0% | 216.1 | 81,031 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 214.68 per share. | 14 May 2024 | 1,804 | 416,658 (2%) | 0% | 214.7 | 387,285 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 213.85 per share. | 14 May 2024 | 2,190 | 418,462 (2%) | 0% | 213.9 | 468,342 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 212.85 per share. | 14 May 2024 | 1,363 | 420,652 (2%) | 0% | 212.9 | 290,116 | Common Stock |
| Frederick B. Craves | Director | Sale of securities on an exchange or to another person at price $ 211.84 per share. | 14 May 2024 | 5,009 | 422,015 (2%) | 0% | 211.8 | 1,061,127 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 244.12 per share. | 08 Apr 2024 | 3,730 | 206,834 (1%) | 0% | 244.1 | 910,566 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 242.95 per share. | 08 Apr 2024 | 1,441 | 210,564 (1%) | 0% | 243.0 | 350,094 | Common Stock |
| Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 08 Apr 2024 | 26,270 | 212,005 (1%) | 0% | 9.5 | 248,252 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 248.59 per share. | 08 Apr 2024 | 4,866 | 185,735 (1%) | 0% | 248.6 | 1,209,642 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 247.76 per share. | 08 Apr 2024 | 3,464 | 190,601 (1%) | 0% | 247.8 | 858,241 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 246.96 per share. | 08 Apr 2024 | 5,028 | 194,065 (1%) | 0% | 247.0 | 1,241,710 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 245.71 per share. | 08 Apr 2024 | 2,078 | 199,093 (1%) | 0% | 245.7 | 510,591 | Common Stock |
| Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2024 | 26,270 | 206,256 | - | - | Stock Option (Right to Buy) | |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 244.86 per share. | 08 Apr 2024 | 5,663 | 201,171 (1%) | 0% | 244.9 | 1,386,646 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 08 Apr 2024 | 2,676 | 461,675 (2%) | 0% | 9.4 | 25,288 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 244.79 per share. | 08 Apr 2024 | 945 | 460,506 (2%) | 0% | 244.8 | 231,325 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 245.69 per share. | 08 Apr 2024 | 300 | 460,206 (2%) | 0% | 245.7 | 73,706 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 246.98 per share. | 08 Apr 2024 | 600 | 459,606 (2%) | 0% | 247.0 | 148,186 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 247.76 per share. | 08 Apr 2024 | 407 | 459,199 (2%) | 0% | 247.8 | 100,838 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 248.58 per share. | 08 Apr 2024 | 200 | 458,999 (2%) | 0% | 248.6 | 49,716 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2024 | 2,676 | 76,564 | - | - | Stock Option (Right to Buy) | |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 243.25 per share. | 08 Apr 2024 | 224 | 461,451 (2%) | 0% | 243.2 | 54,487 | Common Stock |
| Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 03 Apr 2024 | 27,613 | 213,348 (1%) | 0% | 9.5 | 260,943 | Common Stock |
| Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 27,613 | 232,526 | - | - | Stock Option (Right to Buy) | |
| Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 18,710 | 260,139 | - | - | Stock Option (Right to Buy) | |
| Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 27,407 | 278,849 | - | - | Stock Option (Right to Buy) | |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 245.92 per share. | 03 Apr 2024 | 444 | 185,735 (1%) | 0% | 245.9 | 109,189 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 245.35 per share. | 03 Apr 2024 | 5,228 | 186,179 (1%) | 0% | 245.3 | 1,282,669 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 244.22 per share. | 03 Apr 2024 | 3,966 | 191,407 (1%) | 0% | 244.2 | 968,588 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 243.20 per share. | 03 Apr 2024 | 9,264 | 195,373 (1%) | 0% | 243.2 | 2,253,016 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 242.42 per share. | 03 Apr 2024 | 6,679 | 204,637 (1%) | 0% | 242.4 | 1,619,098 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 241.15 per share. | 03 Apr 2024 | 612 | 211,316 (1%) | 0% | 241.1 | 147,582 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 240.10 per share. | 03 Apr 2024 | 1,420 | 211,928 (1%) | 0% | 240.1 | 340,939 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 248.42 per share. | 03 Apr 2024 | 200 | 185,735 (1%) | 0% | 248.4 | 49,685 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 247.14 per share. | 03 Apr 2024 | 737 | 185,935 (1%) | 0% | 247.1 | 182,141 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 246.13 per share. | 03 Apr 2024 | 1,558 | 186,672 (1%) | 0% | 246.1 | 383,471 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 245.14 per share. | 03 Apr 2024 | 2,549 | 188,230 (1%) | 0% | 245.1 | 624,857 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 244.31 per share. | 03 Apr 2024 | 627 | 190,779 (1%) | 0% | 244.3 | 153,185 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 243.00 per share. | 03 Apr 2024 | 1,467 | 191,406 (1%) | 0% | 243.0 | 356,482 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 242.25 per share. | 03 Apr 2024 | 5,299 | 192,873 (1%) | 0% | 242.2 | 1,283,679 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 241.07 per share. | 03 Apr 2024 | 6,273 | 198,172 (1%) | 0% | 241.1 | 1,512,222 | Common Stock |
| Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 03 Apr 2024 | 18,710 | 204,445 (1%) | 0% | 9.5 | 176,810 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 246.31 per share. | 03 Apr 2024 | 1,821 | 185,735 (1%) | 0% | 246.3 | 448,530 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 245.34 per share. | 03 Apr 2024 | 18,806 | 187,556 (1%) | 0% | 245.3 | 4,613,823 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 244.58 per share. | 03 Apr 2024 | 4,301 | 206,362 (1%) | 0% | 244.6 | 1,051,959 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 243.64 per share. | 03 Apr 2024 | 2,294 | 210,663 (1%) | 0% | 243.6 | 558,921 | Common Stock |
| Paul A. Friedman | Director | Sale of securities on an exchange or to another person at price $ 242.00 per share. | 03 Apr 2024 | 185 | 212,957 (1%) | 0% | 242 | 44,770 | Common Stock |
| Paul A. Friedman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 03 Apr 2024 | 27,407 | 213,142 (1%) | 0% | 9.4 | 258,996 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 242.00 per share. | 03 Apr 2024 | 135 | 486,709 (3%) | 0% | 242 | 32,670 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 27,506 | 79,240 | - | - | Stock Option (Right to Buy) | |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 18,537 | 106,746 | - | - | Stock Option (Right to Buy) | |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Apr 2024 | 27,845 | 125,283 | - | - | Stock Option (Right to Buy) | |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 245.53 per share. | 03 Apr 2024 | 5,278 | 458,999 (2%) | 0% | 245.5 | 1,295,924 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 244.45 per share. | 03 Apr 2024 | 2,079 | 464,277 (3%) | 0% | 244.5 | 508,213 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 243.33 per share. | 03 Apr 2024 | 8,989 | 466,356 (3%) | 0% | 243.3 | 2,187,288 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 242.61 per share. | 03 Apr 2024 | 8,817 | 475,345 (3%) | 0% | 242.6 | 2,139,069 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 241.14 per share. | 03 Apr 2024 | 700 | 484,162 (3%) | 0% | 241.1 | 168,799 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 240.11 per share. | 03 Apr 2024 | 1,643 | 484,862 (3%) | 0% | 240.1 | 394,497 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 03 Apr 2024 | 27,845 | 486,844 (3%) | 0% | 9.4 | 263,135 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 03 Apr 2024 | 27,506 | 486,505 (3%) | 0% | 9.5 | 259,932 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 248.23 per share. | 03 Apr 2024 | 100 | 458,999 (2%) | 0% | 248.2 | 24,823 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 247.23 per share. | 03 Apr 2024 | 711 | 459,099 (2%) | 0% | 247.2 | 175,778 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 246.01 per share. | 03 Apr 2024 | 1,653 | 459,810 (2%) | 0% | 246.0 | 406,658 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 245.06 per share. | 03 Apr 2024 | 2,734 | 461,463 (2%) | 0% | 245.1 | 670,006 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 244.01 per share. | 03 Apr 2024 | 435 | 464,197 (3%) | 0% | 244.0 | 106,143 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 242.71 per share. | 03 Apr 2024 | 3,085 | 464,632 (3%) | 0% | 242.7 | 748,765 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 241.85 per share. | 03 Apr 2024 | 5,619 | 467,717 (3%) | 0% | 241.9 | 1,358,971 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 240.88 per share. | 03 Apr 2024 | 4,200 | 473,336 (3%) | 0% | 240.9 | 1,011,679 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 03 Apr 2024 | 18,537 | 477,536 (3%) | 0% | 9.5 | 175,175 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 246.33 per share. | 03 Apr 2024 | 2,089 | 458,999 (2%) | 0% | 246.3 | 514,573 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 245.34 per share. | 03 Apr 2024 | 18,917 | 461,088 (2%) | 0% | 245.3 | 4,641,014 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 244.68 per share. | 03 Apr 2024 | 4,070 | 480,005 (3%) | 0% | 244.7 | 995,854 | Common Stock |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Sale of securities on an exchange or to another person at price $ 243.68 per share. | 03 Apr 2024 | 2,634 | 484,075 (3%) | 0% | 243.7 | 641,866 | Common Stock |
| Kenneth M. Bate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 01 Apr 2024 | 10,000 | 11,198 (0%) | 0% | 9.5 | 94,500 | Common Stock |
| Kenneth M. Bate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 11,212 | 0 | - | - | Stock Option (Right to Buy) | |
| Kenneth M. Bate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 1,277 | 11,212 | - | - | Stock Option (Right to Buy) | |
| Kenneth M. Bate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kenneth M. Bate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 249.00 per share. | 01 Apr 2024 | 7 | 1,198 (0%) | 0% | 249 | 1,743 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 248.49 per share. | 01 Apr 2024 | 193 | 1,205 (0%) | 0% | 248.5 | 47,958 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 246.88 per share. | 01 Apr 2024 | 100 | 1,398 (0%) | 0% | 246.9 | 24,688 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 246.20 per share. | 01 Apr 2024 | 567 | 1,498 (0%) | 0% | 246.2 | 139,597 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 244.96 per share. | 01 Apr 2024 | 2,080 | 2,065 (0%) | 0% | 245.0 | 509,527 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 244.27 per share. | 01 Apr 2024 | 7,048 | 4,145 (0%) | 0% | 244.3 | 1,721,630 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 243.28 per share. | 01 Apr 2024 | 1,217 | 11,193 (0%) | 0% | 243.3 | 296,075 | Common Stock |
| Kenneth M. Bate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 105.08 per share. | 01 Apr 2024 | 11,212 | 12,410 (0%) | 0% | 105.1 | 1,178,157 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 266.91 per share. | 01 Apr 2024 | 274 | 1,198 (0%) | 0% | 266.9 | 73,132 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 265.36 per share. | 01 Apr 2024 | 700 | 1,472 (0%) | 0% | 265.4 | 185,749 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 264.73 per share. | 01 Apr 2024 | 116 | 2,172 (0%) | 0% | 264.7 | 30,709 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 263.08 per share. | 01 Apr 2024 | 143 | 2,288 (0%) | 0% | 263.1 | 37,621 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 262.18 per share. | 01 Apr 2024 | 841 | 2,431 (0%) | 0% | 262.2 | 220,493 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 259.13 per share. | 01 Apr 2024 | 200 | 3,272 (0%) | 0% | 259.1 | 51,826 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 258.24 per share. | 01 Apr 2024 | 2,104 | 3,472 (0%) | 0% | 258.2 | 543,339 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 257.33 per share. | 01 Apr 2024 | 2,790 | 5,576 (0%) | 0% | 257.3 | 717,940 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 256.49 per share. | 01 Apr 2024 | 7,411 | 8,366 (0%) | 0% | 256.5 | 1,900,850 | Common Stock |
| Kenneth M. Bate | Director | Sale of securities on an exchange or to another person at price $ 255.62 per share. | 01 Apr 2024 | 6,698 | 15,777 (0%) | 0% | 255.6 | 1,712,119 | Common Stock |
| Kenneth M. Bate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 105.08 per share. | 01 Apr 2024 | 1,277 | 22,475 (0%) | 0% | 105.1 | 134,187 | Common Stock |
| Kenneth M. Bate | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.45 per share. | 01 Apr 2024 | 10,000 | 21,198 (0%) | 0% | 100.5 | 1,004,500 | Common Stock |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 256.88 per share. | 01 Apr 2024 | 3,900 | 13,011 (0%) | 0% | 256.9 | 1,001,836 | Common Stock |
| Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 6,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 5,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 267.07 per share. | 01 Apr 2024 | 300 | 10,298 (0%) | 0% | 267.1 | 80,122 | Common Stock |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 265.28 per share. | 01 Apr 2024 | 713 | 10,598 (0%) | 0% | 265.3 | 189,145 | Common Stock |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 259.07 per share. | 01 Apr 2024 | 100 | 11,311 (0%) | 0% | 259.1 | 25,907 | Common Stock |
| Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.36 per share. | 01 Apr 2024 | 5,000 | 15,298 (0%) | 0% | 7.4 | 36,800 | Common Stock |
| Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 111.06 per share. | 01 Apr 2024 | 6,000 | 21,298 (0%) | 0% | 111.1 | 666,360 | Common Stock |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 255.90 per share. | 01 Apr 2024 | 4,387 | 16,911 (0%) | 0% | 255.9 | 1,122,629 | Common Stock |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 257.94 per share. | 01 Apr 2024 | 1,600 | 11,411 (0%) | 0% | 257.9 | 412,696 | Common Stock |
| James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 244.19 per share. | 01 Apr 2024 | 6,279 | 4,989 (0%) | 0% | 244.2 | 1,533,286 | Common Stock |
| James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.45 per share. | 01 Apr 2024 | 20,000 | 21,198 (0%) | 0% | 100.5 | 2,009,000 | Common Stock |
| James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 105.08 per share. | 01 Apr 2024 | 1,577 | 22,775 (0%) | 0% | 105.1 | 165,711 | Common Stock |
| James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 255.64 per share. | 01 Apr 2024 | 6,809 | 15,966 (0%) | 0% | 255.6 | 1,740,630 | Common Stock |
| James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 256.50 per share. | 01 Apr 2024 | 7,401 | 8,565 (0%) | 0% | 256.5 | 1,898,371 | Common Stock |
| James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 257.30 per share. | 01 Apr 2024 | 3,604 | 4,961 (0%) | 0% | 257.3 | 927,302 | Common Stock |
| James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 258.28 per share. | 01 Apr 2024 | 1,460 | 3,501 (0%) | 0% | 258.3 | 377,094 | Common Stock |
| James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 259.11 per share. | 01 Apr 2024 | 200 | 3,301 (0%) | 0% | 259.1 | 51,822 | Common Stock |
| James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 262.00 per share. | 01 Apr 2024 | 800 | 2,501 (0%) | 0% | 262.0 | 209,604 | Common Stock |
| James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 263.31 per share. | 01 Apr 2024 | 178 | 2,323 (0%) | 0% | 263.3 | 46,870 | Common Stock |
| James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 264.89 per share. | 01 Apr 2024 | 351 | 1,972 (0%) | 0% | 264.9 | 92,977 | Common Stock |
| James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 265.49 per share. | 01 Apr 2024 | 500 | 1,472 (0%) | 0% | 265.5 | 132,743 | Common Stock |
| James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 266.91 per share. | 01 Apr 2024 | 274 | 1,198 (0%) | 0% | 266.9 | 73,132 | Common Stock |
| James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 105.08 per share. | 01 Apr 2024 | 10,912 | 12,110 (0%) | 0% | 105.1 | 1,146,633 | Common Stock |
| James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 243.26 per share. | 01 Apr 2024 | 842 | 11,268 (0%) | 0% | 243.3 | 204,821 | Common Stock |
| James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 244.89 per share. | 01 Apr 2024 | 2,991 | 1,998 (0%) | 0% | 244.9 | 732,480 | Common Stock |
| James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 246.30 per share. | 01 Apr 2024 | 557 | 1,441 (0%) | 0% | 246.3 | 137,187 | Common Stock |
| James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 247.02 per share. | 01 Apr 2024 | 43 | 1,398 (0%) | 0% | 247.0 | 10,622 | Common Stock |
| James M. Daly | Director | Sale of securities on an exchange or to another person at price $ 248.45 per share. | 01 Apr 2024 | 200 | 1,198 (0%) | 0% | 248.5 | 49,690 | Common Stock |
| James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 1,577 | 10,912 | - | - | Stock Option (Right to Buy) | |
| James M. Daly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 10,912 | 0 | - | - | Stock Option (Right to Buy) | |
| Howarth Alex | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 7,238 | 7,238 | - | - | Stock Option (Right to Buy) | |
| Huntsman Carole | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 3,639 | 11,473 (0%) | 0% | 0 | Common Stock | |
| Carole Huntsman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 5,483 | 5,483 | - | - | Stock Option (Right to Buy) | |
| Alex Howarth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 4,803 | 4,803 | - | - | Market Stock Unit | |
| William John Sibold | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 18,459 | 18,459 | - | - | Stock Option (Right to Buy) | |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 2,138 | 2,138 | - | - | Stock Option (Right to Buy) | |
| Carole Huntsman | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 3,639 | 3,639 | - | - | Market Stock Unit | |
| Taub Rebecca A. | Director, Pres., R&D, and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 8,718 | 8,718 | - | - | Stock Option (Right to Buy) | |
| John William Sibold | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 12,250 | 62,250 (0%) | 0% | 0 | Common Stock | |
| Waltermire E. Robert | Senior VP, Chief Pharma Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 1,419 | 1,419 | - | - | Market Stock Unit | |
| Lynch Joseph Brian | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 3,639 | 17,691 (0%) | 0% | 0 | Common Stock | |
| Rebecca Taub A. | Director, Pres., R&D, and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 5,786 | 5,786 | - | - | Market Stock Unit | |
| Lynch Brian Joseph | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 5,483 | 5,483 | - | - | Stock Option (Right to Buy) | |
| Brian Joseph Lynch | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 3,639 | 3,639 | - | - | Market Stock Unit | |
| John William Sibold | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 12,250 | 12,250 | - | - | Market Stock Unit | |
| Rebecca Taub A. | Director, Pres., R&D, and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 5,786 | 20,787 (0%) | 0% | 0 | Common Stock | |
| Alex Howarth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 4,803 | 18,737 (0%) | 0% | 0 | Common Stock | |
| Waltermire E. Robert | Senior VP, Chief Pharma Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 1,419 | 6,536 (0%) | 0% | 0 | Common Stock | |
| Rebecca Taub A. | Director, Pres., R&D, and CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.92 per share. | 16 Jan 2024 | 1,546 | 15,001 (0%) | 0% | 243.9 | 377,100 | Common Stock |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.92 per share. | 16 Jan 2024 | 550 | 5,117 (0%) | 0% | 243.9 | 134,156 | Common Stock |
| Alex Howarth | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.92 per share. | 16 Jan 2024 | 1,067 | 13,934 (0%) | 0% | 243.9 | 260,263 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.92 per share. | 16 Jan 2024 | 949 | 14,052 (0%) | 0% | 243.9 | 231,480 | Common Stock |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 236.00 per share. | 14 Dec 2023 | 1,000 | 6,667 (0%) | 0% | 236 | 236,000 | Common Stock |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 232.00 per share. | 14 Dec 2023 | 1,000 | 5,667 (0%) | 0% | 232 | 232,000 | Common Stock |
| E. Waltermire Robert | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 2,000 | 19,200 | - | - | Stock Option (Right to Buy) | |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.92 per share. | 14 Dec 2023 | 2,000 | 7,667 (0%) | 0% | 87.9 | 175,840 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 2,000 | 17,200 | - | - | Stock Option (Right to Buy) | |
| Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 241.00 per share. | 14 Dec 2023 | 1,000 | 5,667 (0%) | 0% | 241 | 241,000 | Common Stock |
| E. Waltermire Robert | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.92 per share. | 14 Dec 2023 | 2,000 | 7,667 (0%) | 0% | 87.9 | 175,840 | Common Stock |
| Robert Waltermire E. | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 233.00 per share. | 14 Dec 2023 | 1,000 | 6,667 (0%) | 0% | 233 | 233,000 | Common Stock |
| E. Robert Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 216.00 per share. | 12 Dec 2023 | 500 | 6,467 (0%) | 0% | 216 | 108,000 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.92 per share. | 12 Dec 2023 | 2,500 | 8,167 (0%) | 0% | 87.9 | 219,800 | Common Stock |
| Robert Waltermire E. | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 226.00 per share. | 12 Dec 2023 | 1,000 | 5,667 (0%) | 0% | 226 | 226,000 | Common Stock |
| E. Waltermire Robert | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 225.00 per share. | 12 Dec 2023 | 1,500 | 6,667 (0%) | 0% | 225 | 337,500 | Common Stock |
| Waltermire E. Robert | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 219.00 per share. | 12 Dec 2023 | 800 | 5,667 (0%) | 0% | 219 | 175,200 | Common Stock |
| Waltermire E. Robert | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2023 | 1,300 | 23,700 | - | - | Stock Option (Right to Buy) | |
| E. Robert Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2023 | 2,500 | 21,200 | - | - | Stock Option (Right to Buy) | |
| E. Waltermire Robert | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.92 per share. | 12 Dec 2023 | 1,300 | 6,967 (0%) | 0% | 87.9 | 114,296 | Common Stock |
| Craves Frederick B. | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Dec 2023 | 3,557 | 57,062 (0%) | 0% | 0 | Common Stock | |
| Frederick B. Craves | Director | Other type of transaction at price $ 0.00 per share. | 07 Dec 2023 | 46,073 | 1,261 (0%) | 0% | 0 | Common Stock | |
| Frederick B. Craves | Director | Other type of transaction at price $ 0.00 per share. | 07 Dec 2023 | 1,510,521 | 0 (0%) | 9% | 0 | Common Stock | |
| Lynch Joseph Brian | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 221.38 per share. | 04 Dec 2023 | 1,000 | 15,001 (0%) | 0% | 221.4 | 221,380 | Common Stock |
| Joseph Brian Lynch | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2023 | 1,000 | 44,000 | - | - | Stock Option (Right to Buy) | |
| Joseph Lynch Brian | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 73.75 per share. | 04 Dec 2023 | 800 | 15,801 (0%) | 0% | 73.8 | 59,000 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2023 | 1,000 | 43,000 | - | - | Stock Option (Right to Buy) | |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 215.73 per share. | 04 Dec 2023 | 800 | 16,001 (0%) | 0% | 215.7 | 172,584 | Common Stock |
| Joseph Lynch Brian | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.09 per share. | 04 Dec 2023 | 1,000 | 16,001 (0%) | 0% | 87.1 | 87,090 | Common Stock |
| Lynch Brian Joseph | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2023 | 800 | 20,200 | - | - | Stock Option (Right to Buy) | |
| Lynch Brian Joseph | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.09 per share. | 04 Dec 2023 | 1,000 | 16,801 (0%) | 0% | 87.1 | 87,090 | Common Stock |
| Lynch Brian Joseph | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 227.33 per share. | 04 Dec 2023 | 1,000 | 15,001 (0%) | 0% | 227.3 | 227,330 | Common Stock |
| Frederick B. Craves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 1,198 | 362,556 (2%) | 0% | 0 | Common Stock | |
| Kenneth M. Bate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 1,198 | 1,198 (0%) | 0% | 0 | Common Stock | |
| Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 1,198 | 10,298 (0%) | 0% | 0 | Common Stock | |
| James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 1,198 | 1,198 (0%) | 0% | 0 | Common Stock | |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 272.30 per share. | 28 Feb 2023 | 4,100 | 5,667 (0%) | 0% | 272.3 | 1,116,430 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.92 per share. | 28 Feb 2023 | 5,000 | 10,667 (0%) | 0% | 87.9 | 439,600 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 271.03 per share. | 28 Feb 2023 | 900 | 9,767 (0%) | 0% | 271.0 | 243,927 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 5,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 5,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 276.19 per share. | 28 Feb 2023 | 100 | 5,667 (0%) | 0% | 276.2 | 27,619 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 275.53 per share. | 28 Feb 2023 | 1,300 | 5,767 (0%) | 0% | 275.5 | 358,189 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 274.57 per share. | 28 Feb 2023 | 1,672 | 7,067 (0%) | 0% | 274.6 | 459,081 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Sale of securities on an exchange or to another person at price $ 273.44 per share. | 28 Feb 2023 | 1,928 | 8,739 (0%) | 0% | 273.4 | 527,192 | Common Stock |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.92 per share. | 28 Feb 2023 | 5,000 | 10,667 (0%) | 0% | 87.9 | 439,600 | Common Stock |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 296.68 per share. | 17 Jan 2023 | 500 | 9,100 (0%) | 0% | 296.7 | 148,340 | Common Stock |
| Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 105.08 per share. | 17 Jan 2023 | 12,489 | 21,589 (0%) | 0% | 105.1 | 1,312,344 | Common Stock |
| Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.45 per share. | 17 Jan 2023 | 10,000 | 31,589 (0%) | 0% | 100.5 | 1,004,500 | Common Stock |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 285.28 per share. | 17 Jan 2023 | 100 | 31,489 (0%) | 0% | 285.3 | 28,528 | Common Stock |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 287.08 per share. | 17 Jan 2023 | 400 | 31,089 (0%) | 0% | 287.1 | 114,832 | Common Stock |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 288.91 per share. | 17 Jan 2023 | 300 | 30,789 (0%) | 0% | 288.9 | 86,673 | Common Stock |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 290.36 per share. | 17 Jan 2023 | 1,600 | 29,189 (0%) | 0% | 290.4 | 464,576 | Common Stock |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 291.66 per share. | 17 Jan 2023 | 3,325 | 25,864 (0%) | 0% | 291.7 | 969,770 | Common Stock |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 292.68 per share. | 17 Jan 2023 | 5,227 | 20,637 (0%) | 0% | 292.7 | 1,529,838 | Common Stock |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 293.54 per share. | 17 Jan 2023 | 3,548 | 17,089 (0%) | 0% | 293.5 | 1,041,480 | Common Stock |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 294.68 per share. | 17 Jan 2023 | 5,164 | 11,925 (0%) | 0% | 294.7 | 1,521,728 | Common Stock |
| Richard S. Levy | Director | Sale of securities on an exchange or to another person at price $ 295.45 per share. | 17 Jan 2023 | 2,325 | 9,600 (0%) | 0% | 295.4 | 686,921 | Common Stock |
| Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 12,489 | 0 | - | - | Stock Option (Right to buy) | |
| Richard S. Levy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Paul A. Friedman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 26,668 | 26,668 (0%) | 0% | 0 | Common Stock | |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 20,001 | 20,001 (0%) | 0% | 0 | Common Stock | |
| Brian Joseph Lynch | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 15,001 | 15,001 (0%) | 0% | 0 | Common Stock | |
| Alex Howarth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 15,001 | 15,001 (0%) | 0% | 0 | Common Stock | |
| Remy Sukhija | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 15,001 | 15,001 (0%) | 0% | 0 | Common Stock | |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 5,667 | 5,667 (0%) | 0% | 0 | Common Stock | |
| Friedman A. Paul | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.92 per share. | 16 Jan 2023 | 2,254 | 20,001 (0%) | 0% | 243.9 | 549,796 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 285.15 per share. | 03 Jan 2023 | 829 | 2,538 (0%) | 0% | 285.1 | 236,389 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 282.97 per share. | 03 Jan 2023 | 2,628 | 4,916 (0%) | 0% | 283.0 | 743,645 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 283.85 per share. | 03 Jan 2023 | 1,549 | 3,367 (0%) | 0% | 283.9 | 439,684 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 281.97 per share. | 03 Jan 2023 | 2,656 | 7,544 (0%) | 0% | 282.0 | 748,912 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 280.66 per share. | 03 Jan 2023 | 1,800 | 10,200 (0%) | 0% | 280.7 | 505,188 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 91.79 per share. | 03 Jan 2023 | 13,000 | 13,000 (0%) | 0% | 91.8 | 1,193,270 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 279.10 per share. | 03 Jan 2023 | 400 | 12,000 (0%) | 0% | 279.1 | 111,640 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 277.91 per share. | 03 Jan 2023 | 600 | 12,400 (0%) | 0% | 277.9 | 166,746 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 13,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 287.86 per share. | 03 Jan 2023 | 100 | 0 (0%) | 0% | 287.9 | 28,786 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 286.62 per share. | 03 Jan 2023 | 400 | 100 (0%) | 0% | 286.6 | 114,648 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 285.74 per share. | 03 Jan 2023 | 2,038 | 500 (0%) | 0% | 285.7 | 582,338 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 271.27 per share. | 23 Dec 2022 | 800 | 4,700 (0%) | 0% | 271.3 | 217,016 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2022 | 7,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 283.61 per share. | 23 Dec 2022 | 200 | 0 (0%) | 0% | 283.6 | 56,722 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 281.79 per share. | 23 Dec 2022 | 200 | 200 (0%) | 0% | 281.8 | 56,358 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 280.41 per share. | 23 Dec 2022 | 200 | 400 (0%) | 0% | 280.4 | 56,082 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 279.46 per share. | 23 Dec 2022 | 1,100 | 600 (0%) | 0% | 279.5 | 307,406 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 277.77 per share. | 23 Dec 2022 | 361 | 1,700 (0%) | 0% | 277.8 | 100,275 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 276.40 per share. | 23 Dec 2022 | 100 | 2,061 (0%) | 0% | 276.4 | 27,640 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 275.24 per share. | 23 Dec 2022 | 100 | 2,161 (0%) | 0% | 275.2 | 27,524 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 274.70 per share. | 23 Dec 2022 | 400 | 2,261 (0%) | 0% | 274.7 | 109,880 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 273.48 per share. | 23 Dec 2022 | 539 | 2,661 (0%) | 0% | 273.5 | 147,406 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 272.74 per share. | 23 Dec 2022 | 1,500 | 3,200 (0%) | 0% | 272.7 | 409,110 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 91.79 per share. | 23 Dec 2022 | 7,000 | 7,000 (0%) | 0% | 91.8 | 642,530 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 267.88 per share. | 23 Dec 2022 | 500 | 6,500 (0%) | 0% | 267.9 | 133,940 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 268.99 per share. | 23 Dec 2022 | 300 | 6,200 (0%) | 0% | 269.0 | 80,697 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 270.25 per share. | 23 Dec 2022 | 700 | 5,500 (0%) | 0% | 270.3 | 189,175 | Common Stock |
| Remy Sukhija | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2022 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Remy Sukhija | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 271.54 per share. | 23 Dec 2022 | 2,084 | 20,758 (0%) | 0% | 271.5 | 565,889 | Common Stock |
| Remy Sukhija | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 272.68 per share. | 23 Dec 2022 | 5,534 | 15,224 (0%) | 0% | 272.7 | 1,509,011 | Common Stock |
| Remy Sukhija | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 273.54 per share. | 23 Dec 2022 | 2,471 | 12,753 (0%) | 0% | 273.5 | 675,917 | Common Stock |
| Remy Sukhija | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 274.56 per share. | 23 Dec 2022 | 3,019 | 9,734 (0%) | 0% | 274.6 | 828,897 | Common Stock |
| Remy Sukhija | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 275.70 per share. | 23 Dec 2022 | 811 | 8,923 (0%) | 0% | 275.7 | 223,593 | Common Stock |
| Remy Sukhija | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 276.67 per share. | 23 Dec 2022 | 700 | 8,223 (0%) | 0% | 276.7 | 193,669 | Common Stock |
| Remy Sukhija | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 277.83 per share. | 23 Dec 2022 | 700 | 7,523 (0%) | 0% | 277.8 | 194,481 | Common Stock |
| Remy Sukhija | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 279.15 per share. | 23 Dec 2022 | 3,003 | 4,520 (0%) | 0% | 279.1 | 838,287 | Common Stock |
| Remy Sukhija | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 279.96 per share. | 23 Dec 2022 | 2,620 | 1,900 (0%) | 0% | 280.0 | 733,495 | Common Stock |
| Remy Sukhija | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 280.92 per share. | 23 Dec 2022 | 1,000 | 900 (0%) | 0% | 280.9 | 280,920 | Common Stock |
| Remy Sukhija | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 282.13 per share. | 23 Dec 2022 | 400 | 500 (0%) | 0% | 282.1 | 112,852 | Common Stock |
| Remy Sukhija | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 283.43 per share. | 23 Dec 2022 | 400 | 100 (0%) | 0% | 283.4 | 113,372 | Common Stock |
| Remy Sukhija | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 284.65 per share. | 23 Dec 2022 | 100 | 0 (0%) | 0% | 284.7 | 28,465 | Common Stock |
| Remy Sukhija | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 60.26 per share. | 23 Dec 2022 | 30,000 | 30,000 (0%) | 0% | 60.3 | 1,807,800 | Common Stock |
| Remy Sukhija | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 266.04 per share. | 23 Dec 2022 | 593 | 29,407 (0%) | 0% | 266.0 | 157,762 | Common Stock |
| Remy Sukhija | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 267.47 per share. | 23 Dec 2022 | 1,107 | 28,300 (0%) | 0% | 267.5 | 296,089 | Common Stock |
| Remy Sukhija | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 268.50 per share. | 23 Dec 2022 | 1,913 | 26,387 (0%) | 0% | 268.5 | 513,641 | Common Stock |
| Remy Sukhija | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 269.61 per share. | 23 Dec 2022 | 1,476 | 24,911 (0%) | 0% | 269.6 | 397,944 | Common Stock |
| Remy Sukhija | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 270.56 per share. | 23 Dec 2022 | 2,069 | 22,842 (0%) | 0% | 270.6 | 559,789 | Common Stock |
| Brian Joseph Lynch | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Keith R. Gollust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 9,470 | 9,470 | - | - | Stock Option (Right to Buy) | |
| Frederick B. Craves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 9,470 | 9,470 | - | - | Stock Option (Right to Buy) | |
| David V. Milligan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 9,470 | 9,470 | - | - | Stock Option (Right to buy) | |
| Kenneth M. Bate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 9,470 | 9,470 | - | - | Stock Option (Right to Buy) | |
| Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 9,470 | 9,470 | - | - | Stock Option (Right to buy) | |
| James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 9,470 | 9,470 | - | - | Stock Option (Right to Buy) | |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 12,250 | 12,250 | - | - | Call Option | |
| Paul A. Friedman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Rebecca A. Taub | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 61,500 | 61,500 | - | - | Stock Option (Right to Buy) | |
| Brian Joseph Lynch | SVP and General Councel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Alex Howarth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Remy Sukhija | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2021 | 35,000 | 35,000 | - | - | Call Option | |
| Keith R. Gollust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 12,489 | 12,489 | - | - | Stock Option (Right to Buy) | |
| Frederick B. Craves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 12,489 | 12,489 | - | - | Stock Option (Right to Buy) | |
| David V. Milligan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 12,489 | 12,489 | - | - | Stock Option (Right to buy) | |
| Kenneth M. Bate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 12,489 | 12,489 | - | - | Stock Option (Right to Buy) | |
| Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 12,489 | 12,489 | - | - | Stock Option (Right to buy) | |
| James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 12,489 | 12,489 | - | - | Stock Option (Right to Buy) | |
| Alex Howarth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2021 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Marc R. Schneebaum | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| Paul A. Friedman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Rebecca A. Taub | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 44,000 | 44,000 | - | - | Stock Option (Right to Buy) | |
| Brian Joseph Lynch | SVP and General Councel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| Remy Sukhija | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Frederick B. Craves | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 04 Sep 2020 | 1,468,350 | 2,260,791 (14%) | 9% | 0 | Common Stock | |
| Frederick B. Craves | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 04 Sep 2020 | 45,460 | 43,537 (0%) | 0% | 0 | Common Stock | |
| Frederick B. Craves | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 04 Sep 2020 | 31,650 | 49,730 (0%) | 0% | 0 | Common Stock | |
| Frederick B. Craves | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 107.64 per share. | 17 Aug 2020 | 7,303 | 42,875 (0%) | 0% | 107.6 | 786,095 | Common Stock |
| Frederick B. Craves | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 110.73 per share. | 17 Aug 2020 | 12,500 | 60,375 (0%) | 0% | 110.7 | 1,384,125 | Common Stock |
| Frederick B. Craves | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 110.03 per share. | 17 Aug 2020 | 10,197 | 50,178 (0%) | 0% | 110.0 | 1,121,976 | Common Stock |
| Brian Joseph Lynch | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2020 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Keith R. Gollust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 6,000 | 6,000 | - | - | Stock Option (Right to Buy) | |
| Frederick B. Craves | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 6,000 | 6,000 | - | - | Stock Option (Right to Buy) | |
| David V. Milligan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 6,000 | 6,000 | - | - | Stock Option (Right to buy) | |
| Kenneth M. Bate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 6,000 | 6,000 | - | - | Stock Option (Right to Buy) | |
| Richard S. Levy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 6,000 | 6,000 | - | - | Stock Option (Right to buy) | |
| James M. Daly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 6,000 | 6,000 | - | - | Stock Option (Right to Buy) | |
| Frederick B. Craves | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 27 May 2020 | 44,903 | 72,875 (0%) | 0% | 0 | Common Stock | |
| Frederick B. Craves | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 27 May 2020 | 6,772 | 81,380 (0%) | 0% | 0 | Common Stock | |
| Frederick B. Craves | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 27 May 2020 | 360,561 | 3,729,141 (24%) | 2% | 0 | Common Stock | |
| Marc R. Schneebaum | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2020 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| Paul A. Friedman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2020 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Rebecca A. Taub | Director, Pres., R&D, and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2020 | 44,000 | 44,000 | - | - | Stock Option (Right to Buy) | |
| Brian Joseph Lynch | SVP and General Councel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2020 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| Frederick B. Craves | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 105.47 per share. | 13 Dec 2019 | 25,320 | 88,152 (0%) | 0% | 105.5 | 2,670,500 | Common Stock |
| Frederick B. Craves | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 105.47 per share. | 13 Dec 2019 | 1,174,680 | 4,089,702 (26%) | 7% | 105.5 | 123,893,500 | Common Stock |
| Rebecca A. Taub | Director, President of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2019 | 8,000 | 8,000 | - | - | Stock Option (Right to Buy) | |
| Keith R. Gollust | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2019 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Frederick B. Craves | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2019 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| David V. Milligan | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2019 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Kenneth M. Bate | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2019 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Richard S. Levy | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2019 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| James M. Daly | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2019 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Marc R. Schneebaum | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2019 | 28,000 | 28,000 | - | - | Stock Option (Right to Buy) | |
| Paul A. Friedman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2019 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Rebecca A. Taub | Director, Chief Medical Officer, EVP R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2019 | 38,000 | 38,000 | - | - | Stock Option (Right to Buy) | |
| Paul A. Friedman | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 117.88 per share. | 20 Nov 2018 | 4,000 | 161,128 (1%) | 0% | 117.9 | 471,520 | Common Stock |
| Paul A. Friedman | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 124.00 per share. | 19 Nov 2018 | 4,000 | 157,128 (1%) | 0% | 124 | 496,000 | Common Stock |
| Frederick B. Craves | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 125.00 per share. | 19 Nov 2018 | 900 | 298,067 (1%) | 0% | 125 | 112,500 | Common Stock |
| Frederick B. Craves | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 124.57 per share. | 19 Nov 2018 | 1,000 | 297,167 (1%) | 0% | 124.6 | 124,570 | Common Stock |
| Frederick B. Craves | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 123.17 per share. | 19 Nov 2018 | 100 | 296,167 (1%) | 0% | 123.2 | 12,317 | Common Stock |
| David V. Milligan | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Nov 2018 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| David V. Milligan | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.46 per share. | 14 Nov 2018 | 10,000 | 30,000 (0%) | 0% | 16.5 | 164,600 | Common Stock |
| David V. Milligan | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.45 per share. | 18 Sep 2018 | 20,000 | 20,000 (0%) | 0% | 9.5 | 189,000 | Common Stock |
| David V. Milligan | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Sep 2018 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Keith R. Gollust | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Frederick B. Craves | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| David V. Milligan | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Kenneth M. Bate | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Richard S. Levy | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2018 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Marc R. Schneebaum | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 287.46 per share. | 11 Jun 2018 | 10,099 | 41,668 (0%) | 0% | 287.5 | 2,903,059 | Common Stock |
| Marc R. Schneebaum | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 99.75 per share. | 11 Jun 2018 | 5,223 | 49,033 (0%) | 0% | 99.7 | 520,994 | Common Stock |
| Marc R. Schneebaum | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.60 per share. | 11 Jun 2018 | 2,734 | 51,767 (0%) | 0% | 61.6 | 168,414 | Common Stock |
| Marc R. Schneebaum | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jun 2018 | 5,223 | 1,205 | - | - | Stock Option | |
| Marc R. Schneebaum | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jun 2018 | 2,734 | 1,640 | - | - | Stock Option | |
| Paul A. Friedman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 287.46 per share. | 11 Jun 2018 | 73,526 | 655,540 (4%) | 0% | 287.5 | 21,135,784 | Common Stock |
| Frederick B. Craves | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 287.46 per share. | 11 Jun 2018 | 5,908 | 113,472 (0%) | 0% | 287.5 | 1,698,314 | Common Stock |
| Rebecca A. Taub | Director, Chief Medical Officer, EVP R&D | Sale of securities on an exchange or to another person at price $ 287.46 per share. | 11 Jun 2018 | 73,526 | 655,540 (4%) | 0% | 287.5 | 21,135,784 | Common Stock |
| Marc R. Schneebaum | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2018 | 28,000 | 28,000 | - | - | Stock Option (Right to Buy) | |
| Paul A. Friedman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2018 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Rebecca A. Taub | Director, Chief Medical Officer, EVP R&D, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2018 | 38,000 | 38,000 | - | - | Stock Option (Right to Buy) | |
| Richard S. Levy | None | Purchase of securities on an exchange or from another person at price $ 16.08 per share. | 23 Aug 2017 | 100 | 7,200 (0%) | 0% | 16.1 | 1,608 | Common Stock |
| Richard S. Levy | None | Purchase of securities on an exchange or from another person at price $ 16.29 per share. | 23 Aug 2017 | 7 | 9,100 (0%) | 0% | 16.3 | 114 | Common Stock |
| Richard S. Levy | None | Purchase of securities on an exchange or from another person at price $ 16.12 per share. | 23 Aug 2017 | 1,793 | 9,093 (0%) | 0% | 16.1 | 28,903 | Common Stock |
| Richard S. Levy | None | Purchase of securities on an exchange or from another person at price $ 16.11 per share. | 23 Aug 2017 | 100 | 7,300 (0%) | 0% | 16.1 | 1,611 | Common Stock |
| Richard S. Levy | None | Purchase of securities on an exchange or from another person at price $ 16.14 per share. | 22 Aug 2017 | 127 | 7,100 (0%) | 0% | 16.1 | 2,050 | Common Stock |
| Richard S. Levy | None | Purchase of securities on an exchange or from another person at price $ 16.12 per share. | 22 Aug 2017 | 2,944 | 6,973 (0%) | 0% | 16.1 | 47,457 | Common Stock |
| Richard S. Levy | None | Purchase of securities on an exchange or from another person at price $ 15.99 per share. | 22 Aug 2017 | 90 | 3,640 (0%) | 0% | 16.0 | 1,439 | Common Stock |
| Richard S. Levy | None | Purchase of securities on an exchange or from another person at price $ 16.10 per share. | 22 Aug 2017 | 389 | 4,029 (0%) | 0% | 16.1 | 6,263 | Common Stock |
| Richard S. Levy | None | Purchase of securities on an exchange or from another person at price $ 16.02 per share. | 21 Aug 2017 | 200 | 2,310 (0%) | 0% | 16.0 | 3,204 | Common Stock |
| Richard S. Levy | None | Purchase of securities on an exchange or from another person at price $ 16.04 per share. | 21 Aug 2017 | 210 | 2,520 (0%) | 0% | 16.0 | 3,368 | Common Stock |
| Richard S. Levy | None | Purchase of securities on an exchange or from another person at price $ 16.07 per share. | 21 Aug 2017 | 440 | 2,960 (0%) | 0% | 16.1 | 7,071 | Common Stock |
| Richard S. Levy | None | Purchase of securities on an exchange or from another person at price $ 16.09 per share. | 21 Aug 2017 | 590 | 3,550 (0%) | 0% | 16.1 | 9,493 | Common Stock |
| Richard S. Levy | None | Purchase of securities on an exchange or from another person at price $ 15.90 per share. | 21 Aug 2017 | 10 | 1,910 (0%) | 0% | 15.9 | 159 | Common Stock |
| Richard S. Levy | None | Purchase of securities on an exchange or from another person at price $ 15.67 per share. | 21 Aug 2017 | 900 | 900 (0%) | 0% | 15.7 | 14,103 | Common Stock |
| Richard S. Levy | None | Purchase of securities on an exchange or from another person at price $ 15.70 per share. | 21 Aug 2017 | 100 | 1,000 (0%) | 0% | 15.7 | 1,570 | Common Stock |
| Richard S. Levy | None | Purchase of securities on an exchange or from another person at price $ 15.72 per share. | 21 Aug 2017 | 100 | 1,100 (0%) | 0% | 15.7 | 1,572 | Common Stock |